Drugs for Prader-Willi Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 61)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Liraglutide |
Approved |
Phase 4 |
|
204656-20-2 |
44147092 16134956 |
Synonyms:
ARG34LYS26-(N-Ε-(Γ-GLU(N-Α-HEXADECANOYL)))-GLP-1[7-37]
LIRAGLUTIDA
LIRAGLUTIDE
Liraglutide (genetical recombination)
Liraglutide (rDNA origin)
LIRAGLUTIDE RECOMBINANT
LIRAGLUTIDUM
N²⁶-(HEXADECANOYL-GAMMA-GLUTAMYLE)-[34-ARGININE]GLP-1-(7-37)-PEPTIDE
N²⁶-(N-HEXADECANOYL-L-GAMMA-GLUTAMYL)-[34-L-ARGININE]GLUCAGON-LIKE PEPTIDE 1-(7-37)-PEPTIDE
NN 2211
|
NN2211
NN-2211
NN-2211|NN2211|Victoza®
NN9924
NN-9924
NNC 90-1170
NNC-90-1170
SAXENDA
VICTOZA
|
|
2 |
|
Insulin, Globin Zinc |
|
Phase 4 |
|
|
|
3 |
|
Insulin |
|
Phase 4 |
|
|
|
Synonyms:
AFREZZA
EXUBERA
HUMULIN
HUMULIN BR
HUMULIN R
HUMULIN R KWIKPEN
HUMULIN R PEN
INS HUMULIN R
INSULIN
INSULIN (HUMAN)
INSULIN BOVINE
INSULIN BOVINE INSULIN
|
INSULIN HUMAN
INSULIN HUMAN (BIOSYNTHESIS)
INSULIN HUMAN (SYNTHESIS)
INSULIN RECOMBINANT HUMAN
INSULIN RECOMBINANT PURIFIED HUMAN
INSUMAN INFUSAT
MYXREDLIN
NOVOLIN
NOVOLIN R
VELOSULIN
VELOSULIN BR
VELOSULIN BR HUMAN
|
|
4 |
|
Mitogens |
|
Phase 4 |
|
|
|
5 |
|
Hormones |
|
Phase 4 |
|
|
|
6 |
|
Hormone Antagonists |
|
Phase 4 |
|
|
|
7 |
|
Hypoglycemic Agents |
|
Phase 4 |
|
|
|
8 |
|
Incretins |
|
Phase 4 |
|
|
|
9 |
|
Rimonabant |
Approved, Investigational |
Phase 3 |
|
168273-06-1, 158681-13-1 |
104850 |
Synonyms:
5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide
a 281
A 281|Acomplia®|SR 141716
Acomplia
N-(1-Piperidinyl)-1-(2,4-dichlorophenyl)-4-methyl-5-(4-chlorophenyl)-1H-pyrazole-3-carboxamide
N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide hydrochloride
Rimonabant
Rimonabant hydrochloride
Rimonabantum
|
SR 141716
SR 141716a
SR-14171
SR141716
SR-141716
SR141716a
SR-141716A
Zimulti
|
|
10 |
|
Carbetocin |
Approved, Investigational |
Phase 3 |
|
37025-55-1 |
16681432 |
Synonyms:
1-Butanoate-2-(O-methyl-L-tyrosine)-1-carbaoxytocin
1-Butanoic acid-2-(O-methyl-L-tyrosine)-1-carbaoxytocin
1-Butyrate-2-(3-(p-methoxyphenyl)-L-alanine)oxytocin
1-Butyric acid-2-(3-(p-methoxyphenyl)-L-alanine)oxytocin
1-Deamino-1-monocarba-2-(tyr(ome))-oxytocin
CARBETOCIN
Carbetocina
Carbetocino
|
Carbetocinum
Dcomot
Deamino-2-O-methyltyrosine-1-carbaoxytocin
Depotocin
LV-101
PABAL
Pabal®
|
|
11 |
|
Oxytocin |
Approved, Vet_approved |
Phase 2, Phase 3 |
|
50-56-6 |
439302 53477758 |
Synonyms:
(2S)-2-[({1-[(4R,7S,10S,13S,16S,19R)-19-amino-13-[(2S)-butan-2-yl]-6,9,12,15,18-pentahydroxy-10-[2-(C-hydroxycarbonimidoyl)ethyl]-7-[(C-hydroxycarbonimidoyl)methyl]-16-[(4-hydroxyphenyl)methyl]-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaene-4-carbonyl]pyrrolidin-2-yl}(hydroxy)methylidene)amino]-N-[(C-hydroxycarbonimidoyl)methyl]-4-methylpentanimidate
(Arg8)-vasopressin
(Arg8)-vasotocin
[<sup>3</sup>H]oxytocin
alpha-Hypophamine
Argipressin
Argpressin acetate
Biotinyl-(arg8)-vasopressin
Cys-tyr-ile-GLN-asn-cys-pro-arg-gly-NH2
Cys-tyr-ile-GLN-asn-cys-pro-leu-gly-NH2
Cys-tyr-ile-THR-asn-cys-gly-leu-gly-NH2
Cys-tyr-phe-GLN-asn-cys-pro-arg-gly-NH2
Cys-tyr-phe-GLN-asn-cys-pro-lys-gly-NH2
Disulfide bridge cys1-cys6
Gly-leu-pro-c
Ocytocin
|
ORASTHIN
Oxitocina
OXT
OXYTOCIN
Oxytocin 10 usp units in dextrose 5%
Oxytocin 20 usp units in dextrose 5%
Oxytocin 5 usp units in dextrose 5%
Oxytocin acetate
Oxytocin injection
PITOCIN
SID29217903
SID50111741
SYNTOCINON
SYNTOMETRINE
SYT670
TTA-121
|
|
12 |
|
Octreotide |
Approved, Investigational |
Phase 3 |
|
83150-76-9 |
383414 6400441 |
Synonyms:
(4R,7S,10S,13R,16S,19R)-19-{[(2R)-2-amino-1-hydroxy-3-phenylpropylidene]amino}-10-(4-aminobutyl)-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-6,9,12,15,18-pentahydroxy-7-(1-hydroxyethyl)-13-[(1H-indol-3-yl)methyl]-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaene-4-carboximidate
19-[(2-Amino-1-hydroxy-3-phenylpropylidene)amino]-10-(4-aminobutyl)-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-6,9,12,15,18-pentahydroxy-7-(1-hydroxyethyl)-13-[(1H-indol-3-yl)methyl]-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaene-4-carboximidate
Compound 201 995
Compound 201995
Compound 201-995
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L- cysteinamide cyclic (2->7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L- cysteinamide cyclic (2->7)-disulphide
DRG-0115|Mycapssa®|Sandostatin®|SMS 201,995
Octreotida
Octreotide
Octreotide acetate
OCTREOTIDE ACETATE (PRESERVATIVE FREE)
OCTREOTIDE ACETATE PRESERVATIVE FREE
Octreotide acetate salt
Octreotidum
|
Octrotide
Sandostatin
SANDOSTATIN LAR
Sandostatine
Sandoz 201 995
Sandoz 201995
Sandoz 201-995
SMS 201-995
SMS 201-995 AC
SMS-201-995
SMS-201-995 AC
SMS-201995-AC
SMS995
SMS-995
|
|
13 |
|
Somatostatin |
Approved, Investigational |
Phase 3 |
|
38916-34-6, 51110-01-1 |
53481605 16129706 |
Synonyms:
(5S,8R,14R,17R,20R,23R,26R,29R,32R,35R)-38-[(2-{[(2R)-2-amino-1-hydroxypropylidene]amino}-1-hydroxyethylidene)amino]-20,35-bis(4-aminobutyl)-14,26,29-tribenzyl-7,10,13,16,19,22,25,28,31,34,37-undecahydroxy-32-[(C-hydroxycarbonimidoyl)methyl]-11-(1-hydroxyethyl)-17-[(1S)-1-hydroxyethyl]-8-(hydroxymethyl)-23-[(1H-indol-3-yl)methyl]-1,2-dithia-6,9,12,15,18,21,24,27,30,33,36-undecaazacyclononatriaconta-6,9,12,15,18,21,24,27,30,33,36-undecaene-5-carboxylate
ALA-GLY-CYCLO-[CYS-LYS-ASN-PHE-PHE-TRP-LYS-THR-PHE-THR-SER-CYS]
Growth hormone-inhibiting hormone (ghih)
L-ALANYLGLYCYL-L-CYSTEINYL-L-LYSYL-L-ASPARAGINYL-L-PHENYLALANYL-L-PHENYLALANYL-L-TRYPTOPHYL-L-LYSYL-L-THREONYL-L-PHENYLALANYL-L-THREONYL-L-SERYL-L-CYSTEINE CYCLIC (3-14) DISULFIDE
SOMATOSTATIN
SOMATOSTATIN-1
SOMATOSTATIN-14
SOMATOSTATINA
|
SOMATOSTATINE
SOMATOSTATINUM
Somatotropin release-inhibiting factor (srif)
Somatotropin release-inhibiting hormone
SRIF-14
SYNTHETIC GROWTH HORMONE RELEASE-INHIBITING HORMONE
SYNTHETIC SOMATOSTATIN-14
|
|
14 |
|
Topiramate |
Approved |
Phase 3 |
|
97240-79-4 |
5284627 |
Synonyms:
[(1R,2S,6S,9R)-4,4,11,11-TETRAMETHYL-3,5,7,10,12-PENTAOXATRICYCLO[7.3.0.0^{2,6}]DODECAN-6-YL]METHYL SULFAMATE
2,3:4,5-Bis-O-(1-methylethylidene)-b-D-fructopyranose sulfamate
2,3:4,5-Bis-O-(1-methylethylidene)-b-D-fructopyranose sulfamic acid
2,3:4,5-Bis-O-(1-methylethylidene)-b-D-fructopyranose sulphamate
2,3:4,5-Bis-O-(1-methylethylidene)-b-D-fructopyranose sulphamic acid
2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamic acid
2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulphamate
2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulphamic acid
2,3:4,5-Bis-O-(1-methylethylidene)-β-D-fructopyranose sulfamate
2,3:4,5-Bis-O-(1-methylethylidene)-β-D-fructopyranose sulfamic acid
2,3:4,5-Bis-O-(1-methylethylidene)-β-D-fructopyranose sulphamate
2,3:4,5-Bis-O-(1-methylethylidene)-β-D-fructopyranose sulphamic acid
2,3:4,5-Di-O-isopropylidene-b-D-fructopyranose sulfamate
2,3:4,5-Di-O-isopropylidene-b-D-fructopyranose sulfamic acid
2,3:4,5-Di-O-isopropylidene-b-D-fructopyranose sulphamate
2,3:4,5-Di-O-isopropylidene-b-D-fructopyranose sulphamic acid
2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulfamate
2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulfamic acid
2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulphamate
2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulphamic acid
2,3:4,5-Di-O-isopropylidene-β-D-fructopyranose sulfamate
2,3:4,5-Di-O-isopropylidene-β-D-fructopyranose sulfamic acid
2,3:4,5-Di-O-isopropylidene-β-D-fructopyranose sulphamate
2,3:4,5-Di-O-isopropylidene-β-D-fructopyranose sulphamic acid
2,3-4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
|
Epitomax
epitomax|Eprontia® (liquid formulation)|MCN-4853|RWJ-17021|Topamax®
MCN-4853
QUDEXY XR
RWJ-17021
RWJ-17021-000
Tipiramate
Tipiramate [French]
Tipiramato
Tipiramato [Spanish]
Tipiramic acid
Topamax
Topamax sprinkle
TOPIRAMATE
topiramate tablet
Topiramato
Topiramato [INN-Spanish]
Topiramatum
Topiramatum [INN-Latin]
Topiramic acid
Topomax
TPM
Trokendi XR
USL255
USL-255
|
|
15 |
|
Gastrointestinal Agents |
|
Phase 3 |
|
|
|
16 |
|
Antineoplastic Agents, Hormonal |
|
Phase 3 |
|
|
|
17 |
|
Anticonvulsants |
|
Phase 3 |
|
|
|
18 |
|
Angiogenesis Inhibitors |
|
Phase 3 |
|
|
|
19 |
|
CKD732 |
|
Phase 3 |
|
|
|
20 |
|
Metoprolol |
Approved, Investigational |
Phase 2 |
|
37350-58-6, 51384-51-1 |
4171 |
Synonyms:
(+/-)-metoprolol
(RS)-Metoprolol
1-(Isopropylamino)-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol
Beatrolol
Beloc
Beloc duriles
Beloc-duriles
BelocDuriles
Betaloc
Betaloc astra
Betaloc-astra
BetalocAstra
Betalok
CGP-2175
CGP-2175C
CGP-2175C|GP-2175E|H-93/26|Lopressor®|Toprol®
CR-XL, Metoprolol
DL-Metoprolol
GP-2175E
H-93/26
Lopresor
Lopresoretic
LOPRESSIDONE
Lopressor
Lopressor HCT
|
Meijoprolol
Metohexal
METOPROLOL
Metoprolol CR XL
Metoprolol CR-XL
Metoprolol succinate
Metoprolol tartrate
Metoprololum
Metroprolol
Preblok
Prelis
Presolol
Seloken
Selopral
Selo-Zok
Seroken
Spesicor
Spesikor
Succinate, metoprolol
Tartrate, metoprolol
Toprol
Toprol XL
ToprolXL
Toprol-XL
|
|
21 |
|
Racemethionine |
Approved, Experimental, Investigational, Nutraceutical |
Phase 2 |
|
59-51-8, 63-68-3, 348-67-4 |
6137 |
Synonyms:
(+-)-Methionine
(+/-)-2-amino-4-(methylmercapto)butyric acid
(2S)-2-Amino-4-(methylsulfanyl)butanoate
(2S)-2-Amino-4-(methylsulfanyl)butanoic acid
(2S)-2-Amino-4-(methylsulphanyl)butanoate
(2S)-2-Amino-4-(methylsulphanyl)butanoic acid
(2S,3R)-2-AMMONIO-3-HYDROXYBUTANOATE
(3R,3'r,6S)-4,5-DIDEHYDRO-5,6-dihydro-b,b-carotene-3,3'-diol
(3R,3'r,6S)-4,5-DIDEHYDRO-5,6-dihydro-BETA,BETA-carotene-3,3'-diol
(3R,3'r,6S)-4,5-DIDEHYDRO-5,6-dihydro-β,β-carotene-3,3'-diol
(L)-Methionine
(S)-(+)-Methionine
(S)-2-Amino-4-(methylthio)butanoate
(S)-2-Amino-4-(methylthio)-butanoate
(S)-2-Amino-4-(methylthio)butanoic acid
(S)-2-Amino-4-(methylthio)-butanoic acid
(S)-2-Amino-4-(methylthio)butyrate
(S)-2-Amino-4-(methylthio)butyric acid
(S)-Methionine
2-amino-4-(methylmercapto)Butyric acid
2-Amino-4-(methylsulfanyl)butanoate
2-Amino-4-(methylsulfanyl)butanoic acid
2-Amino-4-(methylsulphanyl)butanoate
2-Amino-4-(methylsulphanyl)butanoic acid
2-Amino-4-(methylthio)butanoate
2-Amino-4-(methylthio)butanoic acid
2-Amino-4-(methylthio)butyrate
2-amino-4-(methylthio)-Butyric acid
2-Amino-4-(methylthio)butyric acid
2-Amino-4-methylthiobutanoate
2-amino-4-Methylthiobutanoic acid
a-Amino-g-methylmercaptobutyrate
a-Amino-g-methylmercaptobutyric acid
Acimethin
alpha-Amino-alpha-aminobutyric acid
alpha-amino-gamma-(methylthio)Butyric acid
alpha-Amino-gamma-methylmercaptobutyrate
alpha-Amino-gamma-methylmercaptobutyric acid
Bo-xan
Cymethion
DL-2-amino-4-(methylthio)Butanoic acid
DL-2-amino-4-(methylthio)Butyric acid
DL-2-amino-4-(methylthio)-Butyric acid
DL-2-amino-4-Methylthiobutanoic acid
DL-Methionine
DL-Methioninum
e 161b
FEMA 3301
gamma-Methylthio-alpha-aminobutyrate
gamma-Methylthio-alpha-aminobutyric acid
g-Methylthio-a-aminobutyrate
g-Methylthio-a-aminobutyric acid
Hmet
|
H-Met-H
H-Met-OH
L(-)-Amino-alpha-amino-alpha-aminobutyric acid
L(-)-Amino-gamma-methylthiobutyric acid
L-(-)-Methionine
L-(−)-METHIONINE
L-2-Amino-4-(methylthio)butyric acid
L-2-Amino-4methylthiobutyrate
L-2-Amino-4methylthiobutyric acid
L-2-Amino-4-methylthiobutyric acid
L-a-Amino-g-methylmercaptobutyrate
L-a-Amino-g-methylmercaptobutyric acid
L-a-Amino-g-methylthiobutyrate
L-a-Amino-g-methylthiobutyric acid
L-alpha-Amino-gamma-methylmercaptobutyrate
L-alpha-Amino-gamma-methylmercaptobutyric acid
L-alpha-Amino-gamma-methylthiobutyrate
L-alpha-Amino-gamma-methylthiobutyric acid
L-gamma-Methylthio-alpha-aminobutyric acid
Liquimeth
L-Isomer methionine
L-MET
L-Methionin
L-Methionine
L-Methionine Z
L-Methioninum
L-Α-amino-γ-methylmercaptobutyrate
L-Α-amino-γ-methylmercaptobutyric acid
M
Mepron
Met
Methilanin
Methionin
Methionine
Methionine, L isomer
Methionine, L-isomer
Methioninum
Metionina
Neo-methidin
NSC-22946
Padameth
Pedameth
Poly-L-methionine
Polymethionine
Racemethionine
Racemethionine, usan
S-Methionine
S-Methyl-L-homocysteine
Toxin war
Xanthophyll
Α-amino-γ-methylmercaptobutyrate
Α-amino-γ-methylmercaptobutyric acid
|
|
22 |
|
Ubidecarenone |
Approved, Investigational, Nutraceutical |
Phase 2 |
|
303-98-0 |
5281915 |
Synonyms:
(all-e)-2-(3,7,11,15,19,23,27,31,35,39-Decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-2,5-cyclohexadiene-1,4-dione
(all-e)-2,3-Dimethoxy-5-methyl-6-(3,7,11,15,19,23,27,31-octamethyl-2,6,10,14,18,22,26,30-dotriacontaoctaenyl)-2,5-cyclohexadiene-1,4-dione
2-((all-e)-3,7,11,15,19,23,27,31,35,39-Decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-p-benzoquinone
2-(3,7,11,15,19,23,27,31,35,39-Decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-p-benzoquinone
2,3-Dimethoxy-5-methyl-6-decaprenylbenzoquinone
2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-Decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl]-5,6-dimethoxy-3-methyl- 2,5-cyclohexadiene-1,4-dione
2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-Decamethyltetraconta-2,6,10,14,18,22,26,30,34,38-decaen-1-yl]-5,6-dimethoxy-3-methyl-1,4-benzoquinone
4-Ethyl-5-fluoropyrimidine
Adelir
all-trans-Ubiquinone
API 31510
API-31510
Aqua Q 10l10
Aqua Q10
Bio-quinon
Bio-quinone Q10
Coenzyme Q10
Coenzyme Q-10
CO-Enzyme Q10
CoQ
CoQ 10
CoQ10
Ensorb
Kaneka Q10
|
Kudesan
Li-Q-sorb
Liquid-Q
Neuquinon
Neuquinone
NSC-140665
NSC-140865
PureSorb Q 40
Q
Q 10AA
Q 199
Q10
Q-Gel
Q-Gel 100
Q-Ter
Ubidecarenone
UBIDECARENONE FOR SYSTEM SUITABILITY
Ubiquinone
Ubiquinone 10
Ubiquinone 50
Ubiquinone Q10
UBIQUINONE-10
Unbiquinone
Unispheres Q 10
|
|
23 |
|
Antimetabolites |
|
Phase 1, Phase 2 |
|
|
|
24 |
|
Vasodilator Agents |
|
Phase 1, Phase 2 |
|
|
|
25 |
|
Hypolipidemic Agents |
|
Phase 1, Phase 2 |
|
|
|
26 |
|
Nootropic Agents |
|
Phase 1, Phase 2 |
|
|
|
27 |
|
Lipid Regulating Agents |
|
Phase 1, Phase 2 |
|
|
|
28 |
|
Vitamins |
|
Phase 2 |
|
|
|
29 |
|
Trace Elements |
|
Phase 2 |
|
|
|
30 |
|
Ubiquinone |
|
Phase 2 |
|
|
|
31 |
|
Micronutrients |
|
Phase 2 |
|
|
|
32 |
|
Adrenergic beta-Antagonists |
|
Phase 2 |
|
|
|
33 |
|
Adrenergic beta-1 Receptor Antagonists |
|
Phase 2 |
|
|
|
34 |
|
Adrenergic Antagonists |
|
Phase 2 |
|
|
|
35 |
|
Anti-Arrhythmia Agents |
|
Phase 2 |
|
|
|
36 |
|
Sympatholytics |
|
Phase 2 |
|
|
|
37 |
|
Anastrozole |
Approved, Investigational |
|
|
120511-73-1 |
2187 |
Synonyms:
2,2'-(5-(1H-1,2,4-Triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile)
a,a,Alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
alpha,alpha,Alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
Anastrazole
Anastrole
Anastrozol
ANASTROZOLE
Arimidex
Arimidex®
Astra brand OF anastrozole
|
AstraZeneca brand OF anastrozole
ICI D1033
ICI-D1033
NASTROSA
ZD1033
ZD-1033
Zeneca brand OF anastrozole
Zeneca ZD 1033
Α,α,alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
α,α,α',α'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
|
|
38 |
|
Racepinephrine |
Approved, Vet_approved |
|
|
51-43-4, 329-65-7 |
838 5816 |
Synonyms:
(−)-(R)-epinephrine
(-)-(R)-Epinephrine
(-)-3,4-Dihydroxy-a-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-a-[(methylamino)methyl]-benzyl alcohol
(-)-3,4-Dihydroxy-a-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-alpha-[(methylamino)methyl]-benzyl alcohol
(-)-3,4-DIHYDROXY-ALPHA-[(METHYLAMINO)METHYL]BENZYL ALCOHOL(-)-3,4-DIHYDROXY-ALPHA-[(METHYLAMINO)METHYL]-BENZYL ALCOHOL
(-)-3,4-Dihydroxy-alpha-[2-(methylamino)ethyl]benzyl alcohol
(−)-3,4-dihydroxy-α-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-α-((methylamino)methyl)benzyl alcohol
(-)-Adrenaline
(−)-ADRENALINE
(-)-Epinephrine
(+-)-Adrenaline
(+-)-Epinephrine
(R)-(-)-Adnephrine
(R)-(-)-Adrenaline
(R)-(−)-ADRENALINE
(R)-(-)-Epinephrine
(R)-(-)-Epirenamine
(R)-4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
(R)-Adrenaline
(R)-Epinephrine
2-(Methylamino)-1-(3,4-dihydroxyphenyl)ethanol
4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
4-[(1R)-1-HYDROXY-2-METHYLAMINOETHYL]BENZENE-1,2-DIOL
4-[(1R)-1-HYDROXY-2-METHYLAMINO-ETHYL]BENZENE-1,2-DIOL
4-[(1R)-1-HYDROXY-2-METHYLAMINO-ETHYL]PYROCATECHOL
Acetate, epinephrine
Adnephrine
ADREN CO
ADRENACLICK
Adrenal
Adrenalin
adrenalin|Auvi-Q®|Epipen®|l-adrenaline|L-epinephrine|levoepinephrine
Adrenaline
Adrénaline
Adrenaline acid tartrate
Adrenaline bitartrate
Adrenaline hydrochloride
Adrenaline hydrochloride, racemic mixture
Adrenaline, racemic
Adrenaline, racemic mixture
adrenaline|epinephrine
Adrenine
Adrin
Allergan brand OF adrenaline hydrochloride
ANA-GUARD
Ana-kit
ANAPEN
ANAPHYLACTIC SHOCK DRUG KIT
ASMA-VYDRIN
ASTHMAHALER
Auvi-Q
Bird brand OF racepinefrine hydrochloride
Bosmin
Bronkaid mist
BROVON
Chelafrin
DL-Adrenaline
EMERADE
EPI E Z PEN JR
Epifrin
Epiglaufrin
Epinefrin
Epinefrina
Epinephran
Epinephrin
EPINEPHRINE
Epinephrine acetate
Epinephrine bitartrate
EPINEPHRINE HCL
Epinephrine hydrochloride
Epinephrine hydrochloride, racemic mixture
Epinephrine hydrogen tartrate
Epinephrine racemic
Epinephrine, racemic
Epinephrine, racemic mixture
Epinephrinum
Epipen
|
EPIPEN E Z PEN
Epipen JR
EPIPEN JR.
Epirenan
Epitrate
Eppy
Exadrin
Glauposine
GPPE INH SOLN
Hemisine
Hemostasin
Hemostatin
Hydrochloride, racepinephrine
Hypernephrin
Isoptoepinal
JEXT
L-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
L-Adrenaline
L-DETHYLAMINOETHANOLCATECHOL
L-Epinephrine
L-Epirenamine
Levoepinephrine
LEVO-METHYLAMINOETHANOLCATECHOL
Levorenen
Levorenin
Levorenine
Levoreninum
L-Methylaminoethanolcatechol
Lyodrin
Lyophrin
Medihaler-epi
Methylarterenol
Micronefrin
Micronephrine
Mixture adrenaline, racemic
Mixture epinephrine, racemic
Mucidrina
Nephridine
Nieraline
NSC-62786
Paranephrin
Primatene
Primatene mist
R-(-)-Epinephrine
Racemic adrenaline
Racemic epinephrine
Racemic mixture adrenaline
Racemic mixture epinephrine
Racepinefrina
Racepinefrine
Racepinefrinum
Racepinephrine
Racepinephrine hydrochloride
Renaglandin
Renaleptine
Renalina
Renoform
Renostypticin
Renostyptin
RIDDOBRON
RIDDOFAN
RYBARVIN
Scurenaline
Simplene
SOLN MADE TO RYBARVIN FOR
Styptirenal
Supracapsulin
Supranephrane
Suprarenaline
Suprarenin
Surrenine
Sus-phrine
SUS-PHRINE SULFITE FREE
SUS-PHRINE SULFITE-FREE
SYMJEPI
Takamina
TWINJECT
TWINJECT 0.15
TWINJECT 0.3
Vaponefrin
Vasoconstrictine
Vasotonin
|
|
39 |
|
Exenatide |
Approved, Investigational |
|
|
141758-74-9 |
45588096 |
Synonyms:
AC 2993
AC002993
AC-002993
AC2993
AC-2993
AC2993A
AC-2993A
AC-2993LAR
BYDUREON
BYDUREON BCISE
BYDUREON PEN
|
BYETTA
DA-3091
Exenatida
EXENATIDE
EXENATIDE SYNTHETIC
Exendin 4
EXENDIN-4
ITCA-650
LY2148568
LY-2148568
SYNTHETIC EXENDIN-4
|
|
40 |
|
Tangerine |
Approved |
|
|
|
|
41 |
|
Hydrocortisone succinate |
Approved |
|
|
2203-97-6 |
3643 |
Synonyms:
4-(2-{14,17-dihydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0.0,.0,]heptadec-6-en-14-yl}-2-oxoethoxy)-4-oxobutanoate
4-(2-{14,17-dihydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-14-yl}-2-oxoethoxy)-4-oxobutanoate
Cortisol 21-(hydrogen succinate)
Cortisol succinate
HYDROCORTISONE HEMISUCCINATE
|
Hydrocortisone hemisuccinate anhydrous
Hydrocortisone hydrogen succinate
HYDROCORTISONE SUCCINATE
Hydroxycortisone succinate
NSC-7576
|
|
42 |
|
Hydrocortisone acetate |
Approved, Vet_approved |
|
|
50-03-3 |
|
Synonyms:
21-O-acetylcortisol
BARQUINOL HC
CHLOROMYCETIN HYDROCORT
COLIFOAM
CORTEF ACETATE
CORTIFOAM
Cortisol 21-acetate
CORTRIL
CORTUCID
DRICORT
EPIFOAM
FRAMYCORT
FUCIDIN H
GENTICIN HC
GENTISONE HC
|
GPPE EAR SUSP
GPPE EYE CRM
GPPE FOAM AERO
HC45 HYDROCORT
HEMSOL-HC
HEPACORT PLUS
HYDROCAL
HYDROCORTISONE 21-ACETATE
HYDROCORTISONE ACETATE
HYDROCORTONE
LANACORT
MICORT-HC
NEO-CORTEF
NSC-741
ORABASE HCA
|
|
43 |
|
Hydrocortisone |
Approved, Vet_approved |
|
|
50-23-7 |
3640 5754 |
Synonyms:
(11ALPHA,14BETA)-11,17,21-TRIHYDROXYPREGN-4-ENE-3,20-DIONE
(11b)-11,17,21-Trihydroxypregn-4-ene-3,20-dione
(11beta)-11,17,21-Trihydroxypregn-4-ene-3,20-dione
(11Β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
(1S,2R,10S,11S,14S,15S,17S)-14,17-DIHYDROXY-14-(2-HYDROXYACETYL)-2,15-DIMETHYLTETRACYCLO[8.7.0.0^{2,7}.0^{11,15}]HEPTADEC-6-EN-5-ONE
11 Epicortisol
11a-Hydroxycorticosterone
11alpha-Hydroxycorticosterone
11b,17,21-Trihydroxyprogesterone
11b,17a,21-Trihydroxy-4-pregnene-3,20-dione
11beta,17,21-Trihydroxyprogesterone
11beta,17alpha,21-Trihydroxy-4-pregnene-3,20-dione
11beta-Hydrocortisone
11-beta-Hydrocortisone
11beta-Hydroxycortisone
11-beta-Hydroxycortisone
11b-Hydrocortisone
11b-Hydroxycortisone
11-Epicortisol
11-Hydrocortisone
11Β,17α,21-trihydroxy-4-pregnene-3,20-dione
11Β-hydrocortisone
17a-Hydroxycorticosterone
17alpha-Hydroxycorticosterone
17-Hydroxycorticosterone
4-Pregnen-11b,17a,21-triol-3,20-dione
4-Pregnen-11beta,17alpha,21-triol-3,20-dione
4-Pregnen-11β,17α,21-triol-3,20-dione
4-Pregnene-11alpha,21-triol 3,20-dione
4-Pregnene-11b,17a,21-triol-3,20-dione
ACETASOL HC
ACTICO МИХАИЛRT
Acticort
Acticort®|Efmody®|Plenadren®
Aeroseb HC
Aeroseb-HC
Alacort
Ala-cort
Ala-scalp
Algicirtis
Alphaderm
Amberin
Anflam
Anti-inflammatory hormone
Anucort-HC
ANUGESIC HC
Anusol HC
ANUSOL PLUS HC
ANUSOL SOOTHING RELIEF
Anusol-HC
Aquacort
Aquanil HC
Balneol-HC
Barseb HC
Basan-corti
Beta-HC
b-HC
CaldeCORT spray
CALMURID HC
CANESTEN HC
Cetacort
Chronocort
CIPRO HC
Clear aid
Cleiton
Cobadex
Colocort
Compound F
CORLAN
Cor-oticin
Cortanal
Cor-tar-quin
Cort-dome
Cortef
CORTENEM
Cortenema
Cortesal
Corticreme
Cortifair
Cortifan
Cortifoam
Cortiment
Cortisol
Cortisol alcohol
Cortisolonum
Cortisporin
Cortisporin otico
Cortispray
Cortizol
Cortolotion
Cortonema
Cortoxide
Cort-quin
CORTRIL
Cremesone
Cremicort-H
Cutisol
DAKTACORT
DAKTACORT HYDROCORT
Delacort
DERMA CARE HYDROCORT
Dermacort
Derm-aid
DERMASPRAY DEMANG
Dermil
Dermolate
Dihydrocostisone
Dioderm
Dome-cort
Domolene-HC
Drotic
ECONACORT
Ef corlin
Efcorbin
Efcortelan
EFCORTELAN P
Efcortelin
Eldecort
Eldercort
Epicort
Epicortisol
Epiderm H
Esiderm H
EURAX-HC
EURAX-HYDROCORT
Evacort
EXE-CORT
Ficortril
Fiocortril
Flexicort
Foille insetti
Genacort
GERMOLOIDS HC
Glycort
GREGODERM
gyno-Cortisone
HC
|
HC #1
HC #4
HC (HYDROCORTISONE)
HC45
H-Cort
Heb cort
Heb-cort
Hi-cor
Hidalone
hidro-Colisona
Hidrocortisona
Hycort
Hycortol
Hycortole
Hydracort
Hydrasson
hydro-Adreson
hydro-Colisona
Hydrocort
HYDROCORT IN CALAMINE OILY
HYDROCORT IN CETOMACROGOL FOR A
HYDROCORT IN WTE SOFT PARAF
Hydrocortal
Hydrocorticosterone
Hydrocortisone
Hydrocortisone acetate
Hydrocortisone alcohol
Hydrocortisone base
Hydrocortisone butyrate
Hydrocortisone free alcohol
Hydrocortisone in absorbase
Hydrocortisone sodium phosphate
Hydrocortisone valerate
Hydrocortisone, (11 alpha)-isomer
Hydrocortisone, (9 beta,10 alpha,11 alpha)-isomer
Hydrocortisonum
Hydrocortistab
Hydrocortisyl
HYDROCORTONE
HYDRODERM
HYDRODERM HC
hydro-RX
Hydroskin
Hydroxycortisone
Hysone
Hytisone
Hytone
Hytone lotion
Idrocortisone
Incortin-H
Incortin-hydrogen
JUNGLE FOR
Kendall's compound F
Komed HC
Kyypakkaus
Lacticare HC
Lacticare-HC
Lactisona
Locoid
Lubricort
Maintasone
Medicort
Meusicort
Micort-HC
Mildison
MILDISON LIPOCREAM
Milliderm
neo-Cort-dome
neo-Cortef
Neosporin-H ear
Nogenic HC
NSC-10483
Nutracort
NYBADEX
Nystaform-HC
Ophthocort
Optef
Otalgine
Otic-neo-cort-dome
Otobiotic
Otocort
OTOSEPTIL
Otosone-F
OTOSPORIN
Pediotic suspension
Penecort
PERINAL
Permicort
Plenadren
Polcort H
Preparation H hydrocortisone cream
Prepcort
Prestwick_265
Prevex HC
Proctocort
PROCTOCREAM HC
Proctofoam
PROCTOFOAM HC
PROCTOSEDYL
Protocort
QUINOCORT
Racet
Rectoid
Reichstein's substance m
Remederm HC
Sanatison
Scalpicin capilar
Schericur
Scheroson F
SENTIAL HC
Sigmacort
Signef
Stie-cort
Stiefcorcil
Synacort
Systral hydrocort
Tarcortin
Terra-cortril
TERRA-CORTRIL NYSTATIN
Texacort
Timocort
TIMODINE
Topicort
TOPISONE
Transderma H
Traumaide
TRI-CICATRIN
U-cort
Uniderm
UNIROID
UNIROID HC
Vioform-hydrocortisone
VoSol HC
Vytone
XYLOPROCT
Zenoxone
β-HC
|
|
44 |
|
Metyrapone |
Approved, Investigational |
|
|
54-36-4 |
4174 |
Synonyms:
Alliance brand OF metyrapone
MEO885
Mepyrapone
mepyrapone|Metopirone®
Methapyrapone
Methbipyranone
Methopirapone
Methopyrapone
Methopyrinine
Methopyrone
Metirapona
Metopiron
|
Metopirone
Métopirone
Metroprione
Metyrapon
METYRAPONE
Métyrapone
Metyrapone alliance brand
Metyrapone novartis brand
Metyraponum
Novartis brand OF metyrapone
NSC-25265
|
|
45 |
|
Tetracosactide |
Approved |
|
|
16960-16-0 |
16133802 16129617 |
Synonyms:
[<sup>125</sup>I]-ACTH(1-24)|[<sup>125</sup>I]-adrenocorticotropin(1-24)
ACTH (1-24)|adrenocorticotropic hormone (1-24)
ADRENOCORTICOTROPIC HORMONE 1-24
ADRENOCORTICOTROPIC HORMONE FRAGMENT 1-24 HUMAN, RAT
ALPHA(1-24)-CORTICOTROPHIN
ATCH (1-24)
BETA(1-24)-CORTICOTROPHIN
CORTICOTROPIN TETRACOSAPEPTIDE
CORTICOTROPIN-(1-24)
CORTICOTROPIN-(1-24) TETRACOSAPEPTIDE
CORTROSYN
Cortrosyn®
COSYNTROPIN
|
SERTYRSERMETGLUHISPHEARGTRPGLYLYSPROVALGLYLYSLYSARGARGPROVALLYSVALTYRPRO
SYN920
SYNACTHEN
SYNACTHEN DEPOT
SYSMEHFRWGKPVGKKRRPVKVYP
Tetracosactida
TETRACOSACTIDE
TETRACOSACTIDE ACETATE
TETRACOSACTRIN
VICOTROPE
Α1-24-CORTICOTROPHIN
Β1-24-CORTICOTROPHIN
|
|
46 |
|
Arginine |
Approved, Investigational, Nutraceutical |
|
|
74-79-3 |
6322 |
Synonyms:
(2S)-2-Amino-5-(carbamimidamido)pentanoate
(2S)-2-Amino-5-(carbamimidamido)pentanoic acid
(2S)-2-AMINO-5-(DIAMINOMETHYLIDENEAMINO)PENTANOIC ACID
(2S)-2-AMINO-5-[(DIAMINOMETHYLIDENE)AMINO]PENTANOIC ACID
(2S)-2-Amino-5-guanidinopentanoate
(2S)-2-Amino-5-guanidinopentanoic acid
(2S)-2-AMINO-5-GUANIDINO-PENTANOIC ACID
(S)-2-Amino-5-[(aminoiminomethyl)amino]pentanoate
(S)-2-Amino-5-[(aminoiminomethyl)amino]-pentanoate
(S)-2-Amino-5-[(aminoiminomethyl)amino]pentanoic acid
(S)-2-Amino-5-[(aminoiminomethyl)amino]-pentanoic acid
(S)-2-Amino-5-guanidinopentanoate
(S)-2-Amino-5-guanidinopentanoic acid
(S)-2-Amino-5-guanidinovalerate
(S)-2-Amino-5-guanidinovaleric acid
2-Amino-5-guanidinovalerate
2-Amino-5-guanidinovaleric acid
5-[(Aminoiminomethyl)amino]-L-norvaline
Arg
Arginina
Arginine
|
Arginine hydrochloride
Arginine, L isomer
Arginine, L-isomer
DL Arginine acetate, monohydrate
DL-Arginine acetate, monohydrate
Hydrochloride, arginine
L Arginine
L-(+)-Arginine
L-a-Amino-D-guanidinovalerate
L-a-Amino-D-guanidinovaleric acid
L-alpha-Amino-delta-guanidinovalerate
L-alpha-Amino-delta-guanidinovaleric acid
L-Arg
L-Arginin
L-ARGININE
L-Isomer arginine
Monohydrate DL-arginine acetate
N5-(Aminoiminomethyl)-L-ornithine
NSC-206269
R
|
|
47 |
|
Liver Extracts |
|
|
|
|
|
48 |
|
Estrogens |
|
|
|
|
|
49 |
|
Estrogen Receptor Antagonists |
|
|
|
|
|
50 |
|
Estrogen Antagonists |
|
|
|
|
|
Interventional clinical trials:
(show top 50)
(show all 110)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Is There a Sensibility Increased in the Growth Hormone at Child With Prader-Willi Syndrome? |
Completed |
NCT01298180 |
Phase 4 |
Growth hormone (Genotonorm® or Omnitrope®) |
2 |
Treatment With Growth Hormone in Adults With PWS, Effect on Muscular Tone Evaluated by Functional MRI, Relationship With Strength and Body Composition |
Completed |
NCT03616509 |
Phase 4 |
Growth hormone;Placebo |
3 |
Comparison of Therapeutic Oxygen Versus Medical Air for the Treatment of Central Sleep Apnea in Infants and Children With Prader Willi Syndrome: A Proof of Concept Study |
Recruiting |
NCT03031626 |
Phase 4 |
|
4 |
Liraglutide Use in Prader-Willi Syndrome |
Terminated |
NCT01542242 |
Phase 4 |
Liraglutide |
5 |
Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injuries Behavior Associated With Prader-Willi Syndrome |
Withdrawn |
NCT04066088 |
Phase 4 |
Guanfacine extended release (GXR) |
6 |
A Single Arm, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone Injection in Patients With Prader-Willi Syndrome |
Unknown status |
NCT03554031 |
Phase 3 |
Recombinant Human Growth Hormone (rhGH) Injection |
7 |
Effect of Rimonabant, a Cannabinoid Receptor 1 Antagonist on Weight Gain and Body Composition in Adults With Prader Willi Syndrome. |
Unknown status |
NCT00603109 |
Phase 3 |
rimonabant;placebo |
8 |
Growth Hormone Use in Adults With Prader-Willi Syndrome |
Completed |
NCT00444964 |
Phase 3 |
Nutropin AQ |
9 |
Oxytocin Treatment in Neonates and Infants Aged From 0 to 3 Months With Prader-Willi Syndrome : a Study of Safety and Efficacy on Oral and Social Skills and Feeding Behavior of Intranasal Administration of Oxytocin vs Placebo |
Completed |
NCT04283578 |
Phase 3 |
OT;Placebo comparator |
10 |
Phase 3, Randomized, Double-Blind, Placebo-Controlled, 8-week Clinical Study to Assess the Efficacy, Safety, and Tolerability, of Intranasal Carbetocin (LV-101) in Prader-Willi Syndrome (PWS) With Long Term Follow-Up (CARE-PWS) |
Completed |
NCT03649477 |
Phase 3 |
3.2 mg intranasal carbetocin;9.6 mg intranasal carbetocin;placebo |
11 |
Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome. |
Completed |
NCT02527200 |
Phase 3 |
liraglutide;placebo |
12 |
Effects of Intranasal Administration of Oxytocin in Adults With Prader-Willi Syndrome |
Completed |
NCT02804373 |
Phase 2, Phase 3 |
Oxytocin (OXT) continuous;Placebo;Placebo continuous;Oxytocin |
13 |
A Phase III, Multi-center, Randomized, Comparative, Parallel, Open Study to Assess the Efficacy and Safety After Treatment of Eutropin® Inj. Compared to Genotropin® in Infants/Toddlers With Prader-Willi Syndrome |
Completed |
NCT02204163 |
Phase 3 |
Eutropin;Genotropin |
14 |
A Randomized, Double-Blind, Placebo-Controlled Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome |
Completed |
NCT03440814 |
Phase 3 |
DCCR;Placebo for DCCR |
15 |
Long-term Interventional Follow-up Study up to 4 Years of Age of Children With Prader-Willi Syndrome Included in the OTBB3 Clinical Trial and Comparison With an Untreated Cohort of Children With Prader-Willi Syndrome |
Recruiting |
NCT05032326 |
Phase 3 |
Follow-up study of the treated cohort |
16 |
An Open-Label, Long-Term Safety and Efficacy Evaluation of Diazoxide Choline Extended-Release Tablets in Participants With Prader-Willi Syndrome With a Double-Blind, Placebo-Controlled, Randomized Withdrawal Period |
Active, not recruiting |
NCT03714373 |
Phase 3 |
DCCR;Placebo for DCCR |
17 |
A PHASE 3 MULTICENTER, OPEN LABEL, MULTI COHORT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SOMATROPIN IN JAPANESE PARTICIPANTS WITH PRADER-WILLI SYNDROME (PWS) |
Active, not recruiting |
NCT04697381 |
Phase 3 |
|
18 |
Effect of Intranasal Oxytocin on Dysphagia Related to Oropharyngo-oesophageal Dysmotility in Children and Adolescents With Prader-Willi Syndrome: a Phase 3 Study |
Active, not recruiting |
NCT05298085 |
Phase 2, Phase 3 |
Oxytocin nasal spray;Placebo |
19 |
Global Growth Hormone Study in Adults With Prader-Willi Syndroom |
Not yet recruiting |
NCT04484051 |
Phase 3 |
Somatropin;Placebo |
20 |
A Phase 2b/3 Study to Evaluate the Safety, Tolerability, and Effects of Livoletide (AZP-531), an Unacylated Ghrelin Analogue, on Food-related Behaviors in Patients With Prader-Willi Syndrome |
Terminated |
NCT03790865 |
Phase 2, Phase 3 |
Livoletide;Placebo |
21 |
Effect of Somatostatin on Ghrelin Concentrations, Food Seeking Behaviour and Weight in Patients With Prader-Willi Syndrome |
Terminated |
NCT00175305 |
Phase 3 |
Sandostatin LAR |
22 |
Randomized, Placebo Controlled Double-blind Study of the Efficacy of Topiramate on the Symptoms of Irritability - Impulsivity, Overeating and Self-harm in a Population of Patients Suffering From Prader Willi Syndrome Over 8 Weeks |
Terminated |
NCT02810483 |
Phase 3 |
Topiramate;Placebo Comparator |
23 |
Randomized, Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Subcutaneous Beloranib in Suspension) in Obese Subjects With Prader-Willi Syndrome to Evaluate Total Body Weight, Food-related Behavior, and Safety Over 6 Months |
Terminated |
NCT02179151 |
Phase 3 |
ZGN-440 for Injectable Suspension;ZGN-440 Placebo for Injectable Suspension |
24 |
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients With Prader- Willi Syndrome |
Terminated |
NCT05098509 |
Phase 2, Phase 3 |
RAD011;Placebo |
25 |
An Open-Label Study of Diazoxide Choline Controlled-Release Tablet in Patients With Prader-Willi Syndrome |
Withdrawn |
NCT04086810 |
Phase 3 |
DCCR |
26 |
A Phase 3, Open-label Extension Study to Assess the Safety, Tolerability, and Efficacy of RAD011 (Cannabidiol Oral Solution) in Patients With Prader-Willi Syndrome |
Withdrawn |
NCT05387798 |
Phase 3 |
RAD011 |
27 |
A 5 Treatment Period Crossover Pharmacokinetic Study Evaluating Dose Proportionality and Food Effects of Diazoxide Choline Controlled-Release Tablet (DCCR) |
Unknown status |
NCT02893618 |
Phase 2 |
Diazoxide choline controlled-release tablet |
28 |
Treatment of Hyperphagia Behavioral Symptoms in Children and Adults Diagnosed With Prader-Willi Syndrome |
Completed |
NCT01968187 |
Phase 2 |
FE 992097;Placebo |
29 |
Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome |
Completed |
NCT02629991 |
Phase 2 |
Intranasal Oxytocin (IN-OXT) |
30 |
Behavioral Treatment of Obsessive-Compulsive Symptoms in Youth With Prader-Willi Syndrome: A Pilot Project |
Completed |
NCT00742664 |
Phase 1, Phase 2 |
|
31 |
A Dose Titration Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome With a Double-Blind, Placebo-Controlled, Randomized Withdrawal Extension |
Completed |
NCT02034071 |
Phase 1, Phase 2 |
DCCR;Placebo |
32 |
A Phase 2 Study to Evaluate Efficacy, Safety, and Pharmacokinetics of GLWL-01 in the Treatment of Patients With Prader-Willi Syndrome |
Completed |
NCT03274856 |
Phase 2 |
GLWL-01;Placebo |
33 |
A Ph 2, Randomized, Double-Blind, Placebo-controlled Pilot Study to Assess the Effects of RM-493, a Melanocortin 4 Receptor (MC4R) Agonist, in Obese Subjects With Prader-Willi Syndrome (PWS) on Safety, Weight Reduction, and Food-Related Behaviors |
Completed |
NCT02311673 |
Phase 2 |
RM-493;Placebo |
34 |
Intranasal Oxytocin for Treatment of Infants and Children With Prader-Willi Syndrome in Nutritional Phase 1a - Phase 2 Study |
Completed |
NCT03245762 |
Phase 1, Phase 2 |
Oxytocin;Placebo |
35 |
A Double-blind, Randomized, Placebo-controlled, Multiple-dose, Multi-centre Safety and Efficacy Study of Co-administration of Tesofensine/Metoprolol in Subjects With Prader-Willi Syndrome (PWS) |
Completed |
NCT03149445 |
Phase 2 |
Tesofensine/Metoprolol;Placebos |
36 |
Randomized, Double-Blind, Placebo Controlled, Parallel Dose Ranging Phase 2a Trial of ZGN-440 (Subcutaneous Beloranib in Suspension), A Novel Methionine Aminopeptidase 2 Inhibitor, in Over-weight and Obese Subjects With Prader-Willi Syndrome to Evaluate Weight Reduction, Food-related Behavior, Safety, and Pharmacokinetics Over 4 Weeks Followed by Optional 4-Week Open-Label Extension |
Completed |
NCT01818921 |
Phase 2 |
ZGN-440 sterile diluent;1.2 mg ZGN-440 for injectable suspension;1.8 mg ZGN-440 for injectable suspension |
37 |
Evaluation of the Effect of the Oxytocin Administered in Nasal Pulverizing on the Social Skills, the Stress, the Anxiety and the Eating Habits at Grown-up Patients Presenting a Syndrome of Prader-Willi: Pilot Study |
Completed |
NCT01038570 |
Phase 2 |
Syntocinon®/- Spray;Physiological serum (Sodium chloride) |
38 |
Evaluation of Tolerance, Suckling and Food Intake After Repeated Nasals Administrations of Oxytocin in PWS Infants |
Completed |
NCT02205034 |
Phase 1, Phase 2 |
oxytocin |
39 |
Tolerance of Intranasal Administration of OT in Prader-Willi Newborn Babies and Effect on Suck and Food Intake. |
Completed |
NCT01548521 |
Phase 1, Phase 2 |
Oxytocin |
40 |
Understanding the Role of Gut Microbiota in Hyperphagia in Prader-Willi Syndrome |
Recruiting |
NCT05541003 |
Phase 2 |
NBT-NM108 |
41 |
Mitochondrial Complex I Dysfunction in Prader Willi Syndrome: A New Therapeutic Target |
Recruiting |
NCT03831425 |
Phase 2 |
|
42 |
Cannabidivarin (CBDV) vs. Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS) |
Recruiting |
NCT03848481 |
Phase 2 |
CBDV Compound;Placebo |
43 |
A Randomized, Double-blind, Placebo-controlled, Multi-center, 2-part, Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome |
Recruiting |
NCT05322096 |
Phase 2 |
RGH-706;Placebo |
44 |
A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of ARD-101 in Patients With Prader-Willi Syndrome |
Recruiting |
NCT05153434 |
Phase 2 |
ARD-101 |
45 |
Phase 2 Study: Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Children and Adolescents With Prader-Willi Syndrome |
Recruiting |
NCT03197662 |
Phase 2 |
Intranasal Oxytocin (IN-OXT);Matched Placebo |
46 |
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension |
Active, not recruiting |
NCT04257929 |
Phase 2 |
Pitolisant oral tablets;Placebo oral tablet |
47 |
A Phase 2b, Double-blind, Randomized, Placebo-controlled, Multi-center, 16-week Dose Finding, Safety and Efficacy Study With Open-label Extension (OLE) Period of Tesomet in Subjects With Prader-Willi Syndrome |
Suspended |
NCT05198362 |
Phase 2 |
Tesomet |
48 |
A Multicenter, Open-Label Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Patients With Prader-Willi Syndrome |
Terminated |
NCT03458416 |
Phase 2 |
Cannabidiol Oral Solution |
49 |
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution for the Treatment of Subjects With Prader-Willi Syndrome |
Terminated |
NCT02844933 |
Phase 2 |
Cannabidiol;Placebo |
50 |
Transcutaneous Vagus Nerve Stimulation in Children With Prader-Willi Syndrome |
Withdrawn |
NCT04396470 |
Phase 1, Phase 2 |
|
|